Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines

被引：549

作者：

Greco, Francesca ^{[1
]}

Vicent, Maria J. ^{[2
]}

机构：

[1] Univ Reading, Sch Pharm, Reading RGD6 6AD, Berks, England

[2] Ctr Invest Principe Felipe, Polyiner Therapeut Lab, Med Chem Dpt, E-46012 Valencia, Spain

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2009年 / 61卷 / 13期

关键词：

Polymer-conjugate; Polymer therapeutics; Nanomedicine; Targeted drug delivery; Combination therapy; Cancer; N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER-DOXORUBICIN; PACLITAXEL POLIGLUMEX PPX; ENZYME PRODRUG THERAPY; HPMA COPOLYMER; PHASE-I; BREAST-CANCER; TARGETING ANGIOGENESIS; PHOTODYNAMIC THERAPY; TUMOR-CELLS; CHEMOTHERAPY;

D O I：

10.1016/j.addr.2009.05.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The discovery of new molecular targets and the subsequent development of novel anticancer agents are opening new possibilities for drug combination therapy as anticancer treatment. Polymer-drug conjugates are well established for the delivery of a single therapeutic agent, but only in very recent years their use has been extended to the delivery of multi-agent therapy. These early studies revealed the therapeutic potential of this application but raised new challenges (namely, drug loading and drugs ratio, characterisation, and development of suitable carriers) that need to be addressed for a successful optimisation of the system towards clinical applications. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：1203 / 1213

页数：11

共 103 条

[1] Monoclonal antibody therapy of cancer [J].